HTG Molecular Diagnostics, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-11-08: Form 8-K; Period of report 2018-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-09-27: Form 8-K; Period of report 2018-09-21; Description 8.01 Other Events.
- 2018-09-06: Form 8-K; Period of report 2018-09-06; Description 7.01 Regulation FD Disclosure.
- 2018-08-21: Form 8-K; Period of report 2018-08-16; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-11-08 | 8-K | 2018-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2018, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2018. | htgm-8k_20181108.htm |
| 2018-09-27 | 8-K | 2018-09-21 | 8.01 Other Events | htgm-8k_20180921.htm | |
| 2018-09-06 | 8-K | 2018-09-06 | 7.01 Regulation FD Disclosure | htgm-8k_20180906.htm | |
| 2018-08-21 | 8-K | 2018-08-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 HTG Molecular Diagnostics, Inc. (the “Company”) previously entered into letter agreements with each of its named executive officers. | htgm-8k_20180816.htm |
| 2018-08-21 | 8-K | 2018-08-15 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On August 15, 2018, HTG Molecular Diagnostics, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). | htgm-8k_20180815.htm |
| 2018-08-20 | 8-K | 2018-08-15 | 8.01 Other Events | htgm-8k_20180816.htm | |
| 2018-08-07 | 8-K | 2018-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2018, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2018. | htgm-8k_20180807.htm |
| 2018-05-21 | 8-K | 2018-05-16 | 1.02 Termination of a Material Definitive Agreement; 7.01 Regulation FD Disclosure | htgm-8k_20180516.htm | |
| 2018-05-10 | 8-K | 2018-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2018, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2018. | htgm-8k_20180510.htm |
| 2018-04-16 | 8-K | 2018-04-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 10, 2018, our board of directors approved the promotion of John L. Lubniewski to President and Chief Operating Officer, effective immediately. | htgm-8k_20180410.htm |
| 2018-04-04 | 8-K | 2018-03-30 | 8.01 Other Events | htgm-8k_20180330.htm | |
| 2018-03-27 | 8-K | 2018-03-26 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 1.02 The information in Item 1.01 above with respect to the Company’s existing indebtedness under its Loan and Security Agreement with Oxford Finance LLC and Silicon Valley Bank is incorporated by reference into this Item 1.02. 2.03 The information in Item 1.01 above is incorporated by reference into this Item 2.03. | htgm-8k_20180326.htm |
| 2018-03-22 | 8-K | 2018-03-22 | 2.02 Results of Operations and Financial Condition | 2.02 On March 22, 2018, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2017. | htgm-8k_20180322.htm |
| 2018-02-27 | 8-K | 2018-02-23 | 8.01 Other Events | htgm-8k_20180223.htm | |
| 2018-01-31 | 8-K | 2018-01-25 | 8.01 Other Events | 8.01 As previously reported, in May 2016 we entered into a collaboration agreement with Bristol‑Myers Squibb Company (“BMS”), for the development of custom research assays based on our HTG EdgeSeq technology, and for potential laboratory services using and/or supply of such custom research assays. | htgm-8k_20180125.htm |
| 2018-01-31 | 8-K | 2018-01-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Our named executive officers and our principal financial officer (collectively, “Named Executive Officers”) are eligible to receive annual performance-based bonuses pursuant to their employment agreements with us. | htgm-8k_20180125.htm |
| 2018-01-19 | 8-K | 2018-01-18 | 8.01 Other Events | 8.01 On January 18, 2018, we entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 12,100,000 shares of our common stock, par value $0.001 per share. | d528609d8k.htm |
| 2018-01-16 | 8-K | 2018-01-12 | 8.01 Other Events | 8.01 On January 12, 2018, HTG Molecular Diagnostics, Inc. (the “Company”) and QIAGEN Manchester Limited (“QIAGEN”), a U.K. corporation and wholly owned subsidiary of QIAGEN N.V., entered into a third statement of work (“SOW Three”) under the parties’ Master Assay Development, Commercialization and Manufacturing Agreement (“Master Agreement”). | htgm-8k_20180111.htm |
| 2018-01-16 | 8-K | 2018-01-16 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 The information set forth under subsection (ii) of Item 8.01 of this report is incorporated under this Item 2.02 by reference. 8.01 As previously reported, on April 13, 2017 we entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor Fitzgerald”), pursuant to which we may offer and sell, from time to time, through Cantor Fitzgerald, shares of our common stock, par value $0.001 per share, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “ATM Offering”). | d483611d8k.htm |
| 2018-01-04 | 8-K | 2018-01-04 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On January 4, 2018, HTG Molecular Diagnostics, Inc. (the “Company”) issued a press release announcing certain preliminary financial results as of and for the fourth quarter and full year ended December 31, 2017. 8.01 Although the Company’s financial results as of and for the fourth quarter and full year ended December 31, 2017 are not yet finalized, based on currently available information, the Company expects its fourth quarter 2017 revenue to be between $6.9 and $7.2 million, its full year 2017 revenue to be between $13.8 and $14.1 million and its cash and cash equivalents as of December 31, 2017 to be approximately $10.0 million. | htgm-8k_20180104.htm |